[Hepatitis C and diabetes].
Salmerón
J
J
D000818:Animals; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology*; D004347:Drug Interactions; D005234:Fatty Liver / Q000209:etiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D016174:Hepacivirus / Q000235:genetics / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects; D055504:Insulin Receptor Substrate Proteins; D007333:Insulin Resistance; D008103:Liver Cirrhosis / Q000209:etiology; D016031:Liver Transplantation; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011183:Postoperative Complications / Q000453:epidemiology; D012307:Risk Factors; D015398:Signal Transduction; D014764:Viral Proteins / Q000502:physiology
D000998:Antiviral Agents; D007004:Hypoglycemic Agents; C526292:IRS1 protein, human; D007166:Immunosuppressive Agents; D055504:Insulin Receptor Substrate Proteins; C526295:Irs1 protein, mouse; D010750:Phosphoproteins; D014764:Viral Proteins